PathwayReady™ EGFR Signaling Inhibitor Panel

A convenient set consisting of fourteen inhibitors useful for the study of EGFR signaling pathway. The fouteen inhibitors are: 5 mg of AG 490 (Cat. No. 1570-5), 1 mg of Akt Inhibitor, Isozyme-Selective (Cat. No. 1708-1), 5 mg of Canertinib (Cat. No. 1617-5), 5 mg of Gefitinib (Cat. No. 1589-5), 25 mg of Lapatinib Ditosylate (Cat. No. 1624-25), 5 mg of LY 294002 (Cat. No. 1667-5), 5 mg of PD 98059 (Cat. No. 1666-5), 1 mg of PP2 (Cat. No. 1767-1), 1 mg of Rapamycin (Cat. No. 1568-1), 1 mg of SB 203580 (Cat. No. 1712-1), 25 mg of Sorafenib (Cat. No. 1594-25), 5 mg of SP 600125 (Cat. No. 1669-5), 5 mg of Stat3 Inhibitor, S3I-201 (Cat. No. 1775-5), and 1 mg of ZM 336372 (Cat. No. 1789-1).

Alternate Name/Synonyms: EGFR Signaling Inhibitor Panel, PathwayReady™

Appearance: Lyophilized solids

Appearance: N/A

Appearance: See under the individual product

Appearance: See under the individual product

Peptide sequence: N/A

Salt Form: No

Molecular Formula: See under the individual product

Molecular Weight: See under the individual product

Cell-Permeable?: Yes

Purity: ≥95% by HPLC

Solubilities: See under the individual product

Handling: Protect from air, light and moisture

Country of Origin: USA

Tag Line: An EGFR Signaling pathway inhibitors set

MDL Number: N/A

PubChem CID: N/A

SMILES: N/A

InChi: N/A

InChi Key: N/A

Category: Biochemicals